Use of Patient Preference Studies in HTA Decision Making: A NICE Perspective

Patient preference studies could provide valuable insights to a National Institute for Health and Care Excellence committee into the preferences patients have for different treatment options, especially if the study sample is representative of the broader patient population. We identify three main u...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The patient : patient-centered outcomes research Jg. 13; H. 2; S. 145 - 149
Hauptverfasser: Bouvy, Jacoline C., Cowie, Luke, Lovett, Rosemary, Morrison, Deborah, Livingstone, Heidi, Crabb, Nick
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Cham Springer International Publishing 01.04.2020
Springer Nature B.V
Schlagworte:
Clinical decision making
Committees
Cost-Benefit Analysis
Current Opinion
Decision making
Drug Development
Experiments
Health Administration
Health Economics
Health services
Humans
Insurance, Health, Reimbursement
Medicine
Medicine & Public Health
Patient Preference
Patients
Pharmacoeconomics and Health Outcomes
Preferences
Public Health
Quality of Life Research
Regulatory agencies
Regulatory approval
Reimbursement
Risk Assessment
State Medicine - organization & administration
Technology Assessment, Biomedical - organization & administration
Testimony
United Kingdom
United Kingdom
United States > US
ISSN:1178-1653, 1178-1661, 1178-1661
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Patient preference studies could provide valuable insights to a National Institute for Health and Care Excellence committee into the preferences patients have for different treatment options, especially if the study sample is representative of the broader patient population. We identify three main uses of patient preference studies along a technology’s pathway from drug development to clinical use: in early clinical development to guide the selection of appropriate endpoints, to inform benefit-risk assessments carried out by regulators and to inform reimbursement decisions made by health technology assessment bodies. In the context of the National Institute for Health and Care Excellence’s methods and processes, we do not see a role for quantitative patient preference data to be directly incorporated into health economic modelling. Rather, we see a role for patient preference studies to be submitted alongside other types of evidence. Examples where patient preference studies might have added value in health technology assessments include cases where two distinctly different treatment options are being compared, when patients have to decide between multiple treatment options, when technologies have important non-health benefits or when a treatment is indicated for a heterogenous population.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1178-1653
1178-1661
1178-1661
DOI:10.1007/s40271-019-00408-4